Maxim Group Begins Coverage on Neonc Technologies (NASDAQ:NTHI)

Maxim Group began coverage on shares of Neonc Technologies (NASDAQ:NTHI) in a report released on Monday. The brokerage set a “buy” rating and a $20.00 price target on the stock. Maxim Group’s price target would indicate a potential upside of 263.64% from the company’s current price.

A number of other analysts have also recently weighed in on NTHI. BTIG Research assumed coverage on Neonc Technologies in a research report on Friday, April 24th. They issued a “buy” rating and a $15.00 price target for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Neonc Technologies in a research note on Friday, March 27th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $17.50.

Neonc Technologies Stock Performance

Shares of NTHI opened at $5.50 on Monday. The company’s fifty day moving average is $6.42 and its 200-day moving average is $8.18. Neonc Technologies has a 12 month low of $3.20 and a 12 month high of $12.99.

Neonc Technologies (NASDAQ:NTHI) last released its quarterly earnings data on Monday, May 18th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.16).

Insider Transactions at Neonc Technologies

In other Neonc Technologies news, President Amir F. Heshmatpour purchased 10,000 shares of the stock in a transaction dated Friday, May 1st. The shares were bought at an average cost of $4.16 per share, with a total value of $41,600.00. Following the completion of the transaction, the president owned 3,072,000 shares in the company, valued at $12,779,520. This trade represents a 0.33% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have bought 80,700 shares of company stock worth $423,590 in the last three months.

Institutional Trading of Neonc Technologies

Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC increased its position in Neonc Technologies by 5,314.8% in the 4th quarter. Barclays PLC now owns 9,151 shares of the company’s stock worth $76,000 after buying an additional 8,982 shares during the period. Foundations Investment Advisors LLC bought a new stake in shares of Neonc Technologies in the third quarter valued at approximately $100,000. Goldman Sachs Group Inc. acquired a new stake in shares of Neonc Technologies in the fourth quarter worth $124,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Neonc Technologies in the fourth quarter worth $126,000. Finally, Royal Bank of Canada bought a new position in Neonc Technologies during the first quarter worth $247,000.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.